Neurogene Inc. Other Operating Income (Expense), Net
Neurogene Inc. (NGNE) reported Other Operating Income (Expense), Net of -$1.35 thousand for the 3-month period ending 2014-09-30, per its 10-Q filed 2014-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherOperatingIncomeExpenseNet · last filed 2014-11-04
- Neurogene Inc. other operating income (expense), net for the quarter ending 2014-09-30 was -$1.35K, a 100.95% decline year-over-year.
- Neurogene Inc. other operating income (expense), net for the quarter ending 2014-06-30 was $195.52K.
- Neurogene Inc. other operating income (expense), net for the quarter ending 2013-09-30 was $142.07K.
- Neurogene Inc. other operating income (expense), net for the quarter ending 2013-06-30 was -$21.31K.
| Period end | Other Operating Income (Expense), Net 3 month | Other Operating Income (Expense), Net 6 month | Other Operating Income (Expense), Net 9 month |
|---|---|---|---|
| 2014-09-30 | -$1.35K 10-Q · filed 2014-11-04 | $194.17K derived: sum of 2 quarters · filed 2014-11-04 | $4.94K 10-Q · filed 2014-11-04 |
| 2014-06-30 | $195.52K 10-Q · filed 2014-08-11 | $6.29K 10-Q · filed 2014-08-11 | |
| 2013-09-30 | $142.07K 10-Q · filed 2014-11-04 | $120.76K derived: sum of 2 quarters · filed 2014-11-04 | $36.70K 10-Q · filed 2014-11-04 |
| 2013-06-30 | -$21.31K 10-Q · filed 2014-08-11 | -$7.47K 10-Q · filed 2014-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |